Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Triptorelin

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    70 result(s) found for: Triptorelin. Displaying page 1 of 4.
    1  2  3  4  Next»
    EudraCT Number: 2021-005719-29 Sponsor Protocol Number: D-FR-52014-245 Start Date*: 2022-08-04
    Sponsor Name:Ipsen Pharma SAS
    Full Title: An open-label, multicentre, single arm study to assess the efficacy and safety of triptorelin 6-month formulation administered subcutaneously in participants with locally advanced and/or metastatic...
    Medical condition: prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    24.1 100000004864 10085679 Locally advanced prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: FR (Completed) BE (Completed) ES (Ongoing) LT (Completed) NL (Completed) CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-000565-39 Sponsor Protocol Number: 2-54-52014-159 Start Date*: 2008-04-18
    Sponsor Name:BEAUFOUR IPSEN PHARMA
    Full Title: FOLLOW-UP OF THE PHASE III, MULTICENTRE, NON COMPARATIVE, ONE SINGLE GROUP, OPEN STUDY TO ASSESS THE LONG-TERM EFFICACY AND TOLERABILITY OF PAMOATE OF TRIPTORELIN 11.25 MG IN CHILDREN WITH PRECOCIO...
    Medical condition: Precocious Puberty
    Disease: Version SOC Term Classification Code Term Level
    9.1 10058084 Precocious puberty LLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2015-001607-30 Sponsor Protocol Number: Debio8206-CPP-301 Start Date*: 2015-04-24
    Sponsor Name:Debiopharm International, S.A.
    Full Title: An open-label, non-comparative, multicenter study on the efficacy, safety, and pharmacokinetics of triptorelin pamoate (embonate) 22.5 mg 6-month formulation in patients suffering from central (gon...
    Medical condition: Central Precocious Puberty
    Disease: Version SOC Term Classification Code Term Level
    18.0 10014698 - Endocrine disorders 10058084 Precocious puberty PT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2022-003857-78 Sponsor Protocol Number: D-CN-52014-244 Start Date*: 2023-06-29
    Sponsor Name:Ipsen Pharma
    Full Title: A phase III, open-label, multicentre, single arm study to assess the efficacy and safety of the triptorelin 6-month formulation in Chinese paediatric participants with central precocious puberty
    Medical condition: Central Precocious Puberty
    Disease:
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2012-005571-14 Sponsor Protocol Number: TIMING Start Date*: 2013-08-02
    Sponsor Name:INSTITUTO DE INVESTIGACION SANITARIA LA FE
    Full Title: CLINICAL TRIAL, SINGLE BLIND, RANDOMIZED, CONTROLLED PROSPECTIVE EVALUATION FOR OPTIMUM TIME INTERVAL BETWEEN ACETATE ADMINISTRATION AND PUNCTURE TRIPTORELIN FOLLICULAR IN IVF TREATMENT
    Medical condition: INFERTILITY
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2012-001279-35 Sponsor Protocol Number: 8-55-52014-200 Start Date*: 2012-09-13
    Sponsor Name:Ipsen Pharma S.A.S
    Full Title: A phase III single arm study to evaluate the efficacy, safety and local tolerability of a subcutaneous 3‑month formulation of triptorelin pamoate (11.25 mg) in patients with locally advanced or met...
    Medical condition: Locally advanced or metastatic prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: LV (Completed) PL (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2012-005326-29 Sponsor Protocol Number: IBCSG_41-13 Start Date*: 2013-11-11
    Sponsor Name:International Breast Cancer Study Group (IBCSG)
    Full Title: A randomized phase II trial evaluating the endocrine activity and efficacy of neoadjuvant degarelix versus triptorelin in premenopausal patients receiving letrozole for locally advanced endocrine r...
    Medical condition: Premenopausal patients with histologically confirmed locally advanced breast cancer and with primary tumor of ER+/PgR+ and HER2 negative or not amplified.
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2005-005644-11 Sponsor Protocol Number: 2-54-52014-143 Start Date*: 2007-07-05
    Sponsor Name:BEAUFOUR IPSEN PHARMA
    Full Title: Phase III, multicentre, non comparative, open and single stage study to assess the efficacy and safety of pamoate of triptorelin 11.25 mg in children with precocious puberty
    Medical condition: Precocious Puberty
    Disease: Version SOC Term Classification Code Term Level
    9.1 10058084 Precocious puberty LLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2022-002963-31 Sponsor Protocol Number: D-CN-52014-243 Start Date*: 2023-01-13
    Sponsor Name:Ipsen Pharma
    Full Title: AN OPEN-LABEL, MULTICENTRE, SINGLE-ARM STUDY TO ASSESS THE EFFICACY AND SAFETY OF TRIPTORELIN 3-MONTH FORMULATION IN CHINESE CHILDREN WITH CENTRAL PRECOCIOUS PUBERTY
    Medical condition: Central Precocious Puberty
    Disease:
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2006-001511-30 Sponsor Protocol Number: 2-55-52014-145 Start Date*: 2006-10-26
    Sponsor Name:Beaufour Ipsen Pharma
    Full Title: A phase III, single arm, multicentre study to evaluate the efficacy and safety of a subcutaneous four-month sustained-release formulation of triptorelin, a gonadotrophin releasing hormone analogue ...
    Medical condition: Locally advanced or metastatic prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    8.1 10060862 Prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: BE (Completed) GB (Prematurely Ended) FR (Completed) PT (Completed) LV (Prematurely Ended) LT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-005058-31 Sponsor Protocol Number: I-48-52014-142 Start Date*: 2006-12-22
    Sponsor Name:IPSEN FARMACEUTICA BV
    Full Title: PHASE II MULTI-CENTRIC, RANDOMISED, OPEN-LABEL, PARALLEL-GROUP STUDY TO ASSESS THE NON-INFERIORITY OF PAMORELIN® 11,25MG SC INJECTED VERSUS PAMORELIN® 11,25MG IM INJECTED IN PATIENTS SUFFERING FROM...
    Medical condition: Patients with advanced (locally or metastatic) prostate cancer scheduled to receive an LHRH analogue as androgen deprivation therapy
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-007055-41 Sponsor Protocol Number: 2-55-52014-151 Start Date*: 2007-04-16
    Sponsor Name:Beaufour Ipsen Pharma - 24, rue Erlanger 75016 Paris FRANCE
    Full Title: A phase II, open-label, multicentre study to evaluate the pharmacodynamic profile, the efficacy and the safety of a 6-month sustained-release formulation of triptorelin in patients with prostate ca...
    Medical condition: Locally advanced or metastatic prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10060862 Prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: LT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-004160-35 Sponsor Protocol Number: ISR-003 Start Date*: 2018-03-13
    Sponsor Name:Immune System Regulation AB (ISR)
    Full Title: A prospective, randomised, controlled, parallel arm, open phase IIa study on the efficacy and safety of the GnRH analogue triptorelin for HIV-1 reservoir reduction in HIV-1 infected male adult pati...
    Medical condition: HIV-1 infection
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: SE (Ongoing) DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-012786-58 Sponsor Protocol Number: 8-79-52014-168 Start Date*: 2009-12-07
    Sponsor Name:Ipsen Pharma SAS
    Full Title: PROSTATE CANCER ANTIGEN-3 (PCA-3) AND TMPRSS2-ERG (T2-ERG) SCORE CHANGES DURING INITIATION OF ANDROGEN DEPRIVATION THERAPY (ADT) WITH TRIPTORELIN 22.5MG IN PATIENTS WITH ADVANCED PROSTATE CANCER (P...
    Medical condition: Locally advanced or metastatic prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    12.0 10060862 Prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (Completed) ES (Completed) LV (Completed) FR (Completed) NL (Completed) LT (Completed) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-019632-12 Sponsor Protocol Number: A-94-5214-178 Start Date*: 2010-10-19
    Sponsor Name:IPSEN Pharma GmbH
    Full Title: A phase II, multicentre, open, prospective, randomised, parallel-group, pharmacodynamic equivalence study on intramuscular versus subcutaneous applications of Triptorelin pamoate (Pamorelin® LA 11....
    Medical condition: advanced prostate cancer (locally advanced or metastatic)
    Disease: Version SOC Term Classification Code Term Level
    15.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2018-001379-20 Sponsor Protocol Number: 009 Start Date*: 2018-05-23
    Sponsor Name:Myovant Sciences GmbH
    Full Title: A Phase 2a Randomized, Double-Blind, Placebo and Active Comparator-Controlled, Parallel Group, Dose-Range Finding Study of MVT-602 in Healthy Premenopausal Women Undergoing Controlled Ovarian Stimu...
    Medical condition: Female infertility
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004872 10021935 Infertility, female, associated with anovulation LLT
    Population Age: Adults Gender: Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2016-004334-17 Sponsor Protocol Number: EORTC-1532-GUCG Start Date*: 2017-09-21
    Sponsor Name:European Organisation for Research and Treatment of Cancer (EORTC)
    Full Title: A phase 2 Randomized Open-Label Study of Oral darolutamide (ODM-201) vs. androgen deprivation therapy (ADT) with LHRH agonists or antagonist in Men with Hormone Naive Prostate Cancer
    Medical condition: Hormone Naive Prostate Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10071119 Hormone-dependent prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: BE (Trial now transitioned) AT (Completed) ES (Ongoing) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2007-005080-10 Sponsor Protocol Number: SHM001 Start Date*: 2008-05-08
    Sponsor Name:University Hospitals of Leicester NHS Trust
    Full Title: Irregular vaginal bleeding with etonorgestrel contraceptive implant - A pilot randomised controlled trial of prophylactic down regulation with a Gonadotrophin releasing hormone analogue prior to im...
    Medical condition: To investigate if a gonadotrophin releasing hormone (GnRH) analogue injection given to women one month before insertion of the contraceptive implant (Implanon®) reduces the common implant side effe...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10046883 Vaginal bleeding LLT
    Population Age: Adults Gender: Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-001590-32 Sponsor Protocol Number: MMC-2016-01 Start Date*: 2018-04-19
    Sponsor Name:Manuel Macía Cortiñas
    Full Title: Comparison of two protocols of controlled ovarian stimulation with highly purified menotropin in low-responder patients according to Bologna criteria treated in Spanish public hospitals.
    Medical condition: PRIMARY INFERTILITY
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004872 10016399 Female infertility (primary) LLT
    Population Age: Adults Gender: Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-002467-22 Sponsor Protocol Number: FSD-PSE-2021-09 Start Date*: 2021-07-02
    Sponsor Name:Fundacion Santiago Dexeus Font
    Full Title: Dual Trigger vs. GnRH-a Trigger for Elective Fertility Preservation. A randomized controlled trial.
    Medical condition: This study is a randomized controlled, superiority trial comparing the number of MII oocytes following final follicle maturation with dual trigger (250 μg rhCG + 0.2mg Triptorelin) or GnRH-a trigge...
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 05 02:29:00 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA